Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.

Inclusion Criteria: 1. Patients should be voluntary to the trial and provide with signed informed consent. 2. Histologically confirmed diagnosis of pancreatic cancer 3. Male or female, Age: 18-79 years old. 4. No recurrence or metastasis was observed from a follow-up of 4 to 8 weeks by CT scan after radical surgery. 5. the value of Carbohydrate Antigen19-9(CA19-9) \< 180U/mL within 12 weeks after surgery. 6. No previous chemotherapy 7. Eastern Cooperative Oncology Group(ECOG) performance status of 0-1 8. normal function of organ system including the followings. * No hematologic dysfunction(Platelets ≥90×10\^9/L; Neutrophil ≥2×109/L;Hemoglobin ≥90g/L). * Serum bilirubin ≤ 1.2 × upper limits of normal(ULN); aminotransferase ≤ 5 × ULN. * Serum creatinine ≤ 1.25× ULN, or creatinine clearance rate(CCR) ≥60mL/min(calculated by Cockcroft-Gault formula). 9. ECOG scored as 0-1. 10. Life expectancy \> 3 months. Exclusion Criteria: 1. Patient is concurrently using other antineoplastic agent. 2. Known severe hypersensitivity to drugs in the regimen. 3. Patient has a concurrent malignancy or has a malignancy within 5 years of study enrollment(with the exception of nonmelanoma skin cancer or cervical carcinoma in situ). 4. Evidence of serious heart disease, including recorded history of congestive heart-failure, uncontrolled serious arrhythmia, angina that needs treatment of drugs, clinical diagnosed cardiac valve disease, history of serious myocardial infarction and intractable hypertension. 5. Evidence of chronic diarrhea(≥4 times/day) or renal dysfunction. 6. Evidence of active infection or active epidemic disease. 7. Psychiatric illness that would prevent the patient from giving informed consent 8. Pregnant or lactating women.